Krishna Komanduri, MD

Articles

Overcoming Barriers to TIL Use in Patients With Solid Tumors

February 23rd 2023

Closing out their discussion on TIL therapy, Drs Sarnaik and Komanduri identify existing barriers to TIL use in clinical practice and how the field might optimize patient access to these regimens.

TIL Therapy: Lessons Learned and Potential Future Directions in Care

February 23rd 2023

Experts Amod Sarnaik, MD, and Krishna Komanduri, MD, consider lessons learned about TILs and CAR T-cell therapy in hematologic cancers, and how they anticipate TILs fitting into treatment paradigms for solid tumors.

Data from Additional Clinical Studies on Tumor-Infiltrating Lymphocyte Therapy

February 16th 2023

Shared insight from Amod Sarnaik, MD, and Krishna Komanduri, MD, on the halted DELTA-1 clinical trial of ITIL-168 in melanoma, followed by a focused discussion of SITC 2022 data on emerging TIL design and manufacturing strategies.

Results From the C-144-01 Trial and Potential Impact on Clinical Practice

February 16th 2023

Expert perspectives on results from C-144-01, which utilized the TIL therapy lifileucel in the setting of metastatic melanoma, and situations in which the regimen might be used in clinical practice.

Tumor-Infiltrating Lymphocyte Therapy: Clinical Data on Biologic Activity

February 9th 2023

A focused discussion on clinical trial data presented at SITC 2022 elucidating the biologic activity of tumor-infiltrating lymphocyte therapies.

Clinical Experience With TIL Therapy for Solid Tumors

February 9th 2023

Amod Sarnaik, MD, and Krishna Komanduri, MD, share their clinical experience with, and practical advice on, tumor-infiltrating lymphocyte therapy for their patients with solid tumors.

Considerations for Use of TILs versus CAR T-cell Therapies

February 2nd 2023

Shared insight on the benefits and drawbacks of using tumor-infiltrating lymphocyte therapy for treatment of solid tumors, as compared to chimeric antigen receptor (CAR) T-cell therapy.

An Overview on Tumor-Infiltrating Lymphocyte Therapy for Solid Tumors

February 2nd 2023

Expert perspectives on the mechanism of action behind tumor-infiltrating lymphocyte (TIL) therapy and how it might address existing unmet needs in the treatment of solid tumors, including melanoma and non–small cell lung cancer.

Dr. Komanduri on Emerging Therapies for Patients With Hematologic Malignancies

January 8th 2016

Krishna Komanduri, MD, professor of Medicine, Microbiology, and Immunology, director, Sylvester Adult Stem Cell Transplant Program, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, discusses future treatments for patients with hematologic malignancies.